Morphine produces analgesia at opiate receptors expressed in nociceptive circuits. , ␦, and opiate receptor subtypes are expressed in circuits that can modulate nociception and receive inputs from endogenous opioid neuropeptide ligands. The roles played by each receptor subtype in nociceptive processing in drug-free and morphine-treated states have not been clear, however. We produced homologous, recombinant , opiate receptor, heterozygous and homozygous knockout animals that displayed Ϸ54% and 0% of wild-type levels of receptor expression, respectively. These mice expressed receptors and ␦ receptors at near wild-type levels. Untreated knockout mice displayed shorter latencies on tail f lick and hot plate tests for spinal and supraspinal nociceptive responses than wild-type mice. These findings support a significant role for endogenous opioid-peptide interactions with opiate receptors in normal nociceptive processing. Morphine failed to significantly reduce nociceptive responses in hot plate or tail f lick tests of homozygous receptor knockout mice, and heterozygote mice displayed right and downward shifts in morphine analgesia dose-effect relationships. These results implicate endogenous opioidpeptide actions at opiate receptors in several tests of nociceptive responsiveness and support receptor mediation of morphine-induced analgesia in tests of spinal and supraspinal analgesia.
Morphine acts at seven transmembrane domain, G proteinlinked receptor products of genes encoding , , and ␦ opiate receptor subtypes (1) (2) (3) (4) (5) (6) (7) (8) (9) . Each of these genes is expressed in neurons in several neuronal circuits implicated in nociception (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . receptor mediation of much morphine-induced analgesia has been postulated (21, 22) . However, studies using compounds with relative preferences for ␦ and receptors have suggested that these other two opiate receptor subtypes also might play significant roles in the analgesic responses induced by morphine-like drugs (22) (23) (24) (25) (26) . The extent to which each of the three opiate receptor subtype gene products might participate in different features of opiate-or morphineinduced analgesia thus has remained unclear. Elucidation of the selective analgesic contributions of each opiate receptor subtype is of substantial potential importance for developing improved analgesic medications with minimal undesirable effects.
Expression of endogenous opioid-peptide agonists, especially those derived from the preproenkephalin and preprodynorphin genes, in circuits associated with pain perception suggests that opioid-peptide interactions with opiate receptors could be well positioned to modulate nociceptive responses in the absence of exogenously administered opiate drugs (10, 12, 14, (27) (28) (29) (30) (31) (32) . Studies of pain responses in animals and humans treated with opiate antagonists, however, have documented modifications in nociception in some but not all studies (33, 34) . These results also have left uncertainty about the power of endogenous opioid-peptide interactions with opiate receptors in day-to-day nociception modulation.
To test roles for morphine-preferring opiate receptors in nociceptive responses in drug-free and opiate-treated animals, we produced homologous, recombinant, receptor knockout mice and tested baseline and morphine-altered pain responses in animals with deletion of one or both receptor gene copies. Data from these mice provide support for the idea that interactions of endogenous peptides with receptors are likely to be involved in nociceptive responses in drug-free animals. They also underscore the large role that the opiate receptor subtype plays in mediating the analgesia produced by morphine in model pain test systems.
MATERIALS AND METHODS
Genomic Cloning and Targeting Vector Construction. A 595-bp genomic hybridization probe recognizing the 5Ј flanking region of the receptor's first exon from the 129͞SvEv mouse strain was amplified using 30 cycles of PCR, 1 g of genomic DNA, and oligonucleotides 5Ј-ATTGCATATGGT-TAGTTGAGTCGGAAGAGTGTTGAGGTAT-3Ј and 5Ј-T G A A T G C T T G C T G C G G A C T C G G T A G G C T G T A ACTGAGAGC-3Ј based on reported sequences (35) and was subcloned into pCRII (Invitrogen) to produce pCRIIm1204-1756. The insert from pCRIIm1204-1756 was radiolabeled by random priming and was used to identify a 16.5-kb opiate receptor genomic fragment from a -FIX II genomic library prepared from the 129 mouse strain (Stratagene) (Fig. 1A) . The 16.5-kb fragment containing 8.3 kb of the 5Ј flanking sequence, the 561-bp first exon, and 7.7 kb of first intronic sequences from the mouse opiate receptor gene (35) was subcloned into pBluescript (pBS) (Stratagene) to produce pBS16.5.
A receptor targeting vector was constructed using a 3.2-kb EcoRV-BglII 5Ј fragment and a 5.1-kb EcoRI 3Ј fragment subcloned into pPGKneo (36) (Fig. 1B) . The final construct, designated pmKO2, contained the herpes simplex virus thymidine kinase (tk) gene driven by the MC1 polyoma enhancer at the 3Ј end of the EcoRI 3Ј fragment. To identify homologous recombinants, 3Ј and 5Ј hybridization probes were prepared by subcloning 183 bp of the 5Ј EcoRV fragment and 420 bp of the 3Ј EcoRI fragments from pBS16.5 into pBS to produce pBS5Ј183 and pBS3Ј420, respectively (Fig. 1C) .
Production of Homologous, Recombinant Embryonic Stem (ES) Cells and Knockout Mice. Twenty five micrograms of pmKO2 DNA was linearized with BamHI and transfected by electroporation into 10 7 AB1 ES cells derived from 129͞SvEv mice (36) (kindly supplied by Allan Bradley, Baylor College of Medicine, Houston). AB1 ES cells were cultured on mitotically inactive SNL76͞7 feeder cells clonally derived from STO cells stably expressing leukemia inhibitory factor and neomycin resistance genes in DMEM containing 15% fetal bovine serum (HyClone) and 0.1 mM ␤-mercaptoethanol (37) . ES cells were selected for homologous recombination by culture in medium containing 500 g͞ml G418 and 2 M gancyclovir (a generous gift of Syntex, Palo Alto, CA) on days 2-7 after transfection. G418-and gancyclovir-resistant colonies were picked on day 8. BamHI digests of DNA prepared from 800 resistant clones were screened by Southern blot analyses using the insert from pBS5Ј-183 radiolabeled by random priming as hybridization probes. Six positive ES cell lines from the doubly resistant colonies displayed the Ϸ20-kb BamHI fragment anticipated of homologous recombinants and readily distinguishable from the 5-kb fragment obtained from wild-type DNA.
Chimeric mice were generated by injecting 15-20 homologous, recombinant ES cells into blastocysts harvested from C57BL͞6J mice and by implanting the blastocysts into the uteri of pseudopregnant CD-1 mice (Charles River Breeding Laboratories) 2.5 days postcoitus (38) . Blastocysts injected with four of the six homologous, recombinant ES cell lines yielded chimeric animals, as assessed by coat color. Southern blot analyses of DNA extracted from tail tip specimens of the offspring of the chimeras revealed that germ line transmission was achieved from two ES cell lines, 1H8 and 5A20 (Fig. 1D) . Fifty-four percent of 103 offspring of matings between chimera from the 1H8 cell line and C57BL͞6J females revealed disrupted receptor alleles, and F 2 homozygote, heterozygote, and wild-type offspring of F 1 ϫ F 1 intercrosses were used for further biochemical and behavioral testing. (8, 39, 40) . In brief, brains were homogenized in 20 volumes of 50 mM Tris⅐HCl (pH 7.4) using a Polytron, and the membranes were centrifuged at 40,000 ϫ g for 15 min at 4ЊC and washed twice with an intervening 25ЊC, 30-min incubation. Washed membranes containing 500 mg of protein were incubated with and ␦ receptor binding buffers each used 50 mM Tris⅐HCl (pH 7.4), ␦ receptor binding required 5 mM MgCl 2 , and Tris⅐HCl (pH 7.8) was used for receptor binding. Reactions were terminated by the addition of 50 mM ice-cold Tris⅐HCl buffer (pH 7.4), and membrane-associated ligand was estimated after rapid filtration over Whatman GF͞B filters using a Brandel (Gaithersburg, MD) apparatus. Nonspecific binding was estimated using 10 mM naloxone for each radioligand. Scatchard analyses were performed using MACLIGAND (R. Williams, University of California, Los Angeles).
receptor immunohistochemistry was performed as described using a polyclonal antiserum with antibodies recognizing the receptor's C terminus, whose specificities have been documented in Western blotting, immunoprecipitation, and light microscopic immunohistochemical and electron microscope immunohistochemical studies (10, 13, 41, 42) .
General Behavioral Characterization. Rotarod testing. Rotarod testing began when mice were placed on a 3-cm diameter rod rotating at 15 rpm (Ugo Basile, Varesse, Italy), and the number of training trials required for them to stay on the rod for 3 min was recorded. Four hours after this training, mice were placed on the rod as it accelerated from 4 to 40 rpm over 5 min, and the time that they could remain on the accelerating rod was noted.
Screen testing. Screen testing assessed the ability of mice to hang onto a 4-mm wire mesh screen after it was quickly inverted, with a 2-min cutoff time (43) .
Spontaneous locomotor activity. Spontaneous locomotor activity was assessed as total distance traveled calculated from the number of infrared beam breaks measured over 45 min when mice were placed individually in 46 ϫ 25 ϫ 19-cm clear plastic cages inside Optovarimex activity monitors (Columbus Instruments, Columbus, OH) to which the mice had not been previously exposed under dim light, sound-attenuated conditions. As one measure of ''emotionality'' (44), the number of fecal boli found after this initial exposure was recorded manually. Habituated locomotor activity was assessed 4 h after the animals' original exposure to the environment.
Passive avoidance training. Passive avoidance training began by moving mice from home cages to 40-sec confinement in the brightly lit side of a two-chamber apparatus (45) . Access to a dimly lit second chamber was then opened, and the time required for the mouse to enter the second chamber was recorded. Upon entry, the mouse was confined to the second chamber, where it received a 1-sec, 0.3-mAmp, scrambled, unescapable foot shock; it was returned to its home cage 1 min later. Testing for retention was performed 24 h later. Mice were removed from home cages, confined to the brightly lit sides of the apparatus for 40 sec, and allowed access to the second chamber, and the time required for entrance into the dimly lit chamber was recorded, to a maximum of 5 min.
Analgesia Testing. For hot plate analgesia testing, mice were placed on a 52, 55, or 58ЊC hot plate, and latency to paw lick was recorded, with a 30-sec cutoff time. For tail flick testing, mice were loosely wrapped in an adsorbent towel, and their tails were immersed Ϸ2 cm into water heated to 50, 53, or 56ЊC. The time after immersion at which the tail flick response was noted was recorded. Cutoff time for this test was 15 sec. Morphine effects were assessed in mice injected s.c. at 20-min intervals with saline and then with an ascending cumulative dosing regimen producing total drug doses of 3, 10, 30, and 56 mg͞kg morphine sulfate s.c. (46) 
RESULTS
Assessing the genotypes of offspring of heterozygote (ϩ͞Ϫ) ϫ heterozygote (ϩ͞Ϫ) matings and comparing them with the results of heterozygote ϫ wild-type matings did not provide evidence for any overall significant reduction in viability of animals with the receptor gene deletion. Genotypes of 151 progeny of ϩ͞Ϫ ϫ ϩ͞Ϫ matings were 18% (Ϫ͞Ϫ), 50% (ϩ͞Ϫ), and 32% (ϩ͞ϩ) genotypes ( 2 ϭ 5.8; P Ͼ 0.05; df ϭ 2), and 178 progeny of ϩ͞Ϫ ϫ ϩ͞ϩ matings were 46.6% (ϩ͞Ϫ) and 53.4% (ϩ͞ϩ) genotypes; values were not different from expected ratios. However, only 33% of the litters from the ϩ͞Ϫ ϫ ϩ͞Ϫ matings produced more than seven pups whereas 51% of the litters of the ϩ͞Ϫ ϫ ϩ͞ϩ matings were of this size.
The ability to produce viable wild-type (ϩ͞ϩ), heterozygote (ϩ͞Ϫ), and homozygote (Ϫ͞Ϫ) knockout mice allowed assessments of the properties of mice of each genotype. Animals of each genotype appear morphologically identical by gross examination, and histologic evaluation of sections from several levels of the brain and spinal cord revealed no obvious differences, including examinations of several areas of high receptor expression ( Fig. 1; data not shown) . Animals of each of three genotypes were indistinguishable from each other in several tests of locomotor skills, learning, and emotionality performed in drug-free conditions. Locomotor activity in a novel environment, habituation to a novel environment, performance on a rotating rod accelerating from 4 to 40 revolutions per minute, and ability to hang suspended on an inverted wire mesh screen were indistinguishable in tests of 7-17 mice of each genotype (data not shown). A test of emotionality (the number of fecal boli emitted under the stress of an open field novelty situation) revealed similar results in animals of each genotype (data not shown). Abilities to acquire and retain a passive avoidance habit tested 24 h after training were similar between animals of each genotype (data not shown). These baseline abilities encouraged us to evaluate the biochemical features and nociceptive responses in these mice.
The knockout animals displayed gene dose-dependent reductions in levels of receptor expression. Saturation analyses of [ 3 H]DAMGO binding to brain membrane receptors revealed negligible specific binding in homozygotes (Ϫ͞Ϫ). The B max value for heterozygote (ϩ͞Ϫ) mice was 58 Ϯ 11 fmol͞mg protein (n ϭ 4), a value that was 54% of the wild-type value (107 Ϯ 14 fmol͞mg protein, n ϭ 4; Fig. 1E ). These findings were consistent with the results of receptor immunostaining. receptor immunoreactivity in several brain regions and in the spinal cord dorsal horn was substantially reduced in heterozygotes (ϩ͞Ϫ) and virtually eliminated in homozygote (Ϫ͞Ϫ) knockout animals (Fig. 1F) .
These receptor depletions were accompanied by no significant changes in binding to or ␦ opiate receptors. In three different cohorts of knockout mice tested on the tail flick assay under drug-free conditions, knockout mice of both ϩ͞Ϫ and Ϫ͞Ϫ genotypes displayed shorter tail flick latencies compared with wild-type mice (ϩ͞ϩ) when tested at 53ЊC (P Ͻ 0.05; n ϭ 15 for Ϫ͞Ϫ, 24 for ϩ͞Ϫ, and 14 for ϩ͞ϩ; Fig. 2 ). Stimulus-response testing revealed significant reductions in latencies in tests at both 50 and 53ЊC (P Ͻ 0.05-corrected for repeated measures; n ϭ 11 for Ϫ͞Ϫ, 20 for ϩ͞Ϫ, and 10 for ϩ͞ϩ; Fig. 2 ) that were not found using a 56ЊC bath temperature (data not shown). These differences were statistically significant for both heterozygous and homozygous animals.
There was also a more modest reduction in the time to first paw lick on the 55ЊC hot plate test in three cohorts of tested, drug-free, homozygote mice compared with wild-type mice (ϩ͞ϩ), which reached statistical significance (P Ͻ 0.05; n ϭ 15 for Ϫ͞Ϫ, n ϭ 24 for ϩ͞Ϫ, and n ϭ 14 for ϩ͞ϩ; Fig. 2 ). Stimulus-response testing revealed trends toward a similar reduction on a 52ЊC hot plate that did not reach statistical significance (P ϭ 0.1; n ϭ 11 for Ϫ͞Ϫ, n ϭ 20 for ϩ͞Ϫ, and n ϭ 10 for ϩ͞ϩ; Fig. 2 ), but little effect on the very short latencies was found at 58ЊC (data not shown). No effect in heterozygotes, as compared with wild-type mice (ϩ͞ϩ), approached statistical significance at any of the three temperatures examined (data not shown).
Morphine dose-effect relationships were analyzed in 12 wild-type, 12 ϩ͞Ϫ, and 10 Ϫ͞Ϫ mice treated with an ascending dose morphine regimen (46) . Wild-type mice displayed powerful morphine-induced analgesic effects on both tail flick (Fig. 3A) and hot plate (Fig. 3B ) tests (P Ͻ 0.001). Heterozygous (ϩ͞Ϫ) knockout animals revealed right and downward shifts in dose-effect relationships for acutely administered morphine. Homozygous (Ϫ͞Ϫ) knockout animals revealed no statistically significant morphine analgesia on either hot plate or tail flick tests at cumulative doses up to 56 mg͞kg. Responses on the tail flick test did display a modest trend toward reduced nociceptive responses at the 56 mg͞kg dose (P ϭ 0.12).
DISCUSSION
Analyses of animals with opiate receptor gene deletions and reduced receptor expression provided novel data concerning receptor involvement in processing of nociceptive information and in the analgesia exerted by acutely administered morphine. The magnitude of the observed effects might not have been anticipated from previous studies suggesting possibly smaller roles for endogenous opioid systems in modulating nociceptive information and more substantial roles for other opiate receptor subtypes in morphine analgesia. The remarkable failure of other opiate receptor subtypes to show striking adaptations to loss of receptors also supports a degree of independence of the regulation of each of these gene products that might not have been anticipated.
The expression of opiate receptors in multiple central and peripheral nervous system neuronal circuits has suggested their involvement in a number of different activities of cortical, subcortical, and spinal circuits (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . The morphine effects on a broad range of physiological functions (including locomotor activity, neuroendocrine and reproductive systems, respiratory control, pupillomotor systems, and nociceptive functions) support the idea that opiate receptors, including the morphine-preferring receptor, could have broad effects in many neural circuits (47). We are currently investigating possible mechanisms that might underlie the modest reduction in the number of Ϫ͞Ϫ animals produced by ϩ͞Ϫ ϫ ϩ͞Ϫ matings. However, failure of the animals born with deleted receptor expression to display any readily observable alteration in a number of locomotor, autonomic, and other functional tests allowed us to examine nociceptive responses in animals without the kinds of gross defects in other systems that control values for the appropriate genotype. Dose-effect relationships were significant for ϩ͞ϩ and ϩ͞Ϫ mice but not for Ϫ͞Ϫ mice. Among genotype differences, dose-response relationships also were significant for animals of each genotype [P Ͻ 0.001, df(2, 120), F ϭ 66 by repeated measures ANOVA]. (B) Dose-response relationships for morphine-induced alterations in latencies on 55ЊC hot plate testing in mice with wild-type (ϩ͞ϩ), heterozygote (ϩ͞Ϫ), and homozygote (Ϫ͞Ϫ) opiate receptor genotypes using a cumulative dose-response paradigm as described. Percentage of maximal analgesia was calculated for each mouse using a 30-sec cutoff time. ‫,ء‬ P Ͻ 0.05 compared with preinjection control values for the appropriate genotype. Doseeffect relationships were significant for ϩ͞ϩ and ϩ͞Ϫ mice but not for Ϫ͞Ϫ mice. Among genotype differences, between dose-response relationships also were significant for animals of each genotype [P Ͻ 0.001, df(2, 124), F ϭ 27 by repeated measures ANOVA]. Max., maximum.
might readily confound measurements of motor responses to nociceptive stimuli.
Absence of substantial changes in brain expression of and ␦ opiate receptors in the receptor knockout animals also provided the opportunity to examine nociceptive responses in animals with grossly intact function in other opiate receptor systems. Conceivably, adaptive changes in other systems could contribute to the behavioral differences in nociceptive responses noted here. However, the animals' normality on a number of functional screening tests and the biochemical observations suggesting that the receptor may be independently regulated suggested that partial or total receptor absence during development may be compatible with normal or near normal function in a number of brain circuits that express opiate receptors.
Circuits modulating nociception may provide an exception to this general picture. Tail flick testing demonstrates that animals with even 50% reductions from wild-type levels of opiate receptor expression display different spinal reflex responses (48) to noxious stimuli than wild-type mice in the absence of exogenous opiate agonists. Conceivably, subtle, adaptive, developmental changes in non-systems in these mice could contribute to these results. However, the data are in accord with studies that have used opiate antagonists to implicate endogenous opioid-peptide interactions with opiate receptors in pain modulation although these studies have demonstrated only modest and variable effects (34) . Preliminary data examining effects of up to 500 g͞kg s.c. naloxone in wild-type mice of the genotype used here also demonstrate no clear trend toward hyperalgesia (I.S., M.F., and G.R.U., unpublished observation). The data also fit well with the substantial modification of analgesia induced by exogenous opiate drugs in these same mice, as noted below.
The significant alterations in the 50 and 53ЊC tail flick tests of spinal analgesia in untreated receptor ϩ͞Ϫ and Ϫ͞Ϫ mice contrasted with the fact that hot plate testing of largely supraspinal analgesia (48) yielded significant differences only for Ϫ͞Ϫ mice studied at 55ЊC. These results fit with data obtained from hot plate testing of transgenic mice that overexpress receptors in the catecholaminergic neurons that are thought to make large contributions to these supraspinal analgesic mechanisms (ref. 34 ; L.L.M, I.S., and G.R.U., unpublished observations). Drug-free testing of these animals revealed only a small trend toward enhanced latency on this test that does not reach significance although these overexpressing mice did show enhanced morphine potency and power in this test by left and upward shifts in morphine dose-effect relationships (L.L.M., I.S., and G.R.U., unpublished observations). Conceivably, action of endogenous opioid peptides at receptors may be of more importance for spinal analgesia than for supraspinal analgesia (48) , in which neurons using other neurotransmitters and neurotransmitter receptors may play more substantial roles.
Reduced receptor expression exerted several distinct influences on responses to acute morphine administration in hot plate and tail flick tests. Elimination of receptors in Ϫ͞Ϫ animals virtually abolished morphine's effects on nociceptive responses in both tests. receptor ϩ͞Ϫ mice displayed right and downward shifts in morphine dose-effect relationships, consistent with lower morphine potencies and efficacies in tests of both spinal and supraspinal analgesia. Comparisons of these morphine effects with those in unpretreated mice suggest that endogenous opioid-peptide͞ receptor interactions might play roles similar to those of morphine͞ receptor interactions in spinal analgesic mechanisms such as those tested by the tail flick procedure. Comparisons of results in the hot plate tests, however, suggest that morphine may recruit supraspinal -mediated mechanisms much more powerfully than these mechanisms are engaged by endogenous opioid peptides. These data also fit with the above mentioned enhancement of morphine power and potency in hot plate testing of transgenic mice that overexpress receptors in the catecholaminergic neurons that contribute to supraspinal analgesic mechanisms in the absence of significantly different hot plate responses under drug-free conditions (L.L.M., I.S., and G.R.U., unpublished observations).
Taken together, the current results point toward substantial roles for receptor expression in virtually all of the morphineinduced analgesia that can be assessed in major supraspinal and major spinal models of nociceptive processes. The greater effect on drug-free nociceptive responses in largely spinal tail flick testing than in largely supraspinal hot plate testing suggests that the impact of opiate peptide occupancy of endogenous receptors may be more or less susceptible to adaptive changes in the tail flick than in the hot plate tests. Enhanced understanding of these processes should aid significantly in ongoing efforts to improve therapeutic approaches to pain control so that exogenous pharmacological power is maximized and mechanisms for endogenous pain control are minimally suppressed.
